Retatrutide vs Pemvidutide
Head-to-head comparison of Retatrutide and Pemvidutide for research applications. Both peptides are studied for Weight Management and Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Retatrutide | Pemvidutide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Dual GLP-1/Glucagon Agonist |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). | Pemvidutide is a dual-agonist peptide that activates both the GLP-1 receptor and the glucagon receptor. |
| Evidence Rating | B — Phase III / NDA Filed | C — Phase I–II Clinical Trials |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase II completed (MOMENTUM for obesity, IMPACT for NASH/MASH). Phase III anticipated. |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | Common: nausea, vomiting, diarrhea, decreased appetite (consistent with GLP-1 agonist class); GI adverse events are dose-dependent and generally transient; similar profile to other GLP-1 agonists |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | 1.2–2.4 mg SC once weekly (Phase 2 doses) |
| Frequency | Once weekly | Once weekly |
| Molecular Weight | N/A | N/A |
| Half-Life | ~6 days (allows once-weekly dosing) | Suitable for once-weekly dosing (exact value not publicly disclosed) |
Overview
Retatrutide and Pemvidutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Pemvidutide — Mechanism & Evidence
Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist being developed by Altimmune for the treatment of obesity and nonalcoholic steatohepatitis (NASH/MASH). It is a once-weekly injectable peptide designed to combine GLP-1-mediated appetite suppression with glucagon-mediated increases in energy expenditure and hepatic fat reduction. Phase III development is anticipated.
Key claims: Clinically meaningful weight loss in obesity; Substantial reduction in liver fat; Preserves lean body mass.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Pemvidutide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Pemvidutide: Common: nausea, vomiting, diarrhea, decreased appetite (consistent with GLP-1 agonist class) GI adverse events are dose-dependent and generally transient; similar profile to other GLP-1 agonists Heart rate increase observed, consistent with GLP-1 agonist class
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 5mg
5mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe